|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SEC14L1 |
Gene summary for SEC14L1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SEC14L1 | Gene ID | 6397 |
| Gene name | SEC14 like lipid binding 1 | |
| Gene Alias | PRELID4A | |
| Cytomap | 17q25.2-q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0002221 | UniProtAcc | A5PLM6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6397 | SEC14L1 | AEH-subject5 | Human | Endometrium | AEH | 1.72e-35 | 8.43e-01 | -0.2953 |
| 6397 | SEC14L1 | EEC-subject4 | Human | Endometrium | EEC | 1.31e-12 | 5.16e-01 | -0.2571 |
| 6397 | SEC14L1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.76e-06 | -1.23e-01 | -0.1869 |
| 6397 | SEC14L1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 8.06e-12 | -5.23e-02 | -0.1875 |
| 6397 | SEC14L1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 4.32e-10 | -5.37e-02 | -0.1883 |
| 6397 | SEC14L1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.13e-03 | 4.48e-02 | -0.1934 |
| 6397 | SEC14L1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.36e-09 | -1.64e-01 | -0.1917 |
| 6397 | SEC14L1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.91e-16 | -1.23e-01 | -0.1916 |
| 6397 | SEC14L1 | LZE2D | Human | Esophagus | HGIN | 8.24e-03 | 2.41e-01 | 0.0642 |
| 6397 | SEC14L1 | LZE4T | Human | Esophagus | ESCC | 1.60e-17 | 3.53e-01 | 0.0811 |
| 6397 | SEC14L1 | LZE7T | Human | Esophagus | ESCC | 1.80e-07 | 3.08e-01 | 0.0667 |
| 6397 | SEC14L1 | LZE8T | Human | Esophagus | ESCC | 3.08e-05 | 7.39e-02 | 0.067 |
| 6397 | SEC14L1 | LZE22T | Human | Esophagus | ESCC | 7.84e-06 | 3.03e-01 | 0.068 |
| 6397 | SEC14L1 | LZE24T | Human | Esophagus | ESCC | 1.98e-22 | 4.55e-01 | 0.0596 |
| 6397 | SEC14L1 | LZE21T | Human | Esophagus | ESCC | 1.80e-02 | 3.32e-01 | 0.0655 |
| 6397 | SEC14L1 | P1T-E | Human | Esophagus | ESCC | 1.09e-04 | 2.77e-01 | 0.0875 |
| 6397 | SEC14L1 | P2T-E | Human | Esophagus | ESCC | 4.69e-26 | 3.14e-01 | 0.1177 |
| 6397 | SEC14L1 | P4T-E | Human | Esophagus | ESCC | 1.01e-14 | 2.20e-01 | 0.1323 |
| 6397 | SEC14L1 | P5T-E | Human | Esophagus | ESCC | 5.29e-12 | 8.73e-02 | 0.1327 |
| 6397 | SEC14L1 | P8T-E | Human | Esophagus | ESCC | 1.67e-29 | 4.75e-01 | 0.0889 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003052210 | Endometrium | AEH | intracellular receptor signaling pathway | 60/2100 | 265/18723 | 7.16e-08 | 3.77e-06 | 60 |
| GO:00395293 | Endometrium | AEH | RIG-I signaling pathway | 11/2100 | 27/18723 | 8.09e-05 | 1.21e-03 | 11 |
| GO:00395353 | Endometrium | AEH | regulation of RIG-I signaling pathway | 9/2100 | 20/18723 | 1.46e-04 | 1.94e-03 | 9 |
| GO:00027535 | Endometrium | AEH | cytoplasmic pattern recognition receptor signaling pathway | 17/2100 | 60/18723 | 2.25e-04 | 2.75e-03 | 17 |
| GO:00096159 | Endometrium | AEH | response to virus | 63/2100 | 367/18723 | 3.81e-04 | 4.10e-03 | 63 |
| GO:00027645 | Endometrium | AEH | immune response-regulating signaling pathway | 76/2100 | 468/18723 | 5.76e-04 | 5.71e-03 | 76 |
| GO:00395312 | Endometrium | AEH | regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 9/2100 | 24/18723 | 7.48e-04 | 7.12e-03 | 9 |
| GO:00985864 | Endometrium | AEH | cellular response to virus | 20/2100 | 84/18723 | 8.14e-04 | 7.66e-03 | 20 |
| GO:00395282 | Endometrium | AEH | cytoplasmic pattern recognition receptor signaling pathway in response to virus | 11/2100 | 34/18723 | 8.45e-04 | 7.82e-03 | 11 |
| GO:00622074 | Endometrium | AEH | regulation of pattern recognition receptor signaling pathway | 23/2100 | 105/18723 | 1.19e-03 | 1.02e-02 | 23 |
| GO:00026838 | Endometrium | AEH | negative regulation of immune system process | 69/2100 | 434/18723 | 1.76e-03 | 1.41e-02 | 69 |
| GO:00022213 | Endometrium | AEH | pattern recognition receptor signaling pathway | 31/2100 | 172/18723 | 5.16e-03 | 3.23e-02 | 31 |
| GO:003052215 | Endometrium | EEC | intracellular receptor signaling pathway | 65/2168 | 265/18723 | 2.52e-09 | 1.96e-07 | 65 |
| GO:000275311 | Endometrium | EEC | cytoplasmic pattern recognition receptor signaling pathway | 20/2168 | 60/18723 | 7.27e-06 | 1.67e-04 | 20 |
| GO:003952911 | Endometrium | EEC | RIG-I signaling pathway | 11/2168 | 27/18723 | 1.08e-04 | 1.49e-03 | 11 |
| GO:000961513 | Endometrium | EEC | response to virus | 66/2168 | 367/18723 | 1.78e-04 | 2.20e-03 | 66 |
| GO:003953511 | Endometrium | EEC | regulation of RIG-I signaling pathway | 9/2168 | 20/18723 | 1.87e-04 | 2.27e-03 | 9 |
| GO:000276412 | Endometrium | EEC | immune response-regulating signaling pathway | 80/2168 | 468/18723 | 2.20e-04 | 2.64e-03 | 80 |
| GO:003953111 | Endometrium | EEC | regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 9/2168 | 24/18723 | 9.45e-04 | 8.45e-03 | 9 |
| GO:000268313 | Endometrium | EEC | negative regulation of immune system process | 72/2168 | 434/18723 | 1.04e-03 | 9.13e-03 | 72 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SEC14L1 | SNV | Missense_Mutation | c.488N>C | p.Ile163Thr | p.I163T | Q92503 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SEC14L1 | SNV | Missense_Mutation | c.841N>G | p.Leu281Val | p.L281V | Q92503 | protein_coding | deleterious(0.02) | possibly_damaging(0.858) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| SEC14L1 | SNV | Missense_Mutation | novel | c.481N>A | p.Glu161Lys | p.E161K | Q92503 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SEC14L1 | SNV | Missense_Mutation | novel | c.935N>G | p.Tyr312Cys | p.Y312C | Q92503 | protein_coding | tolerated(0.17) | benign(0.018) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SEC14L1 | SNV | Missense_Mutation | rs773798440 | c.2026N>A | p.Gly676Ser | p.G676S | Q92503 | protein_coding | tolerated(0.57) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SEC14L1 | SNV | Missense_Mutation | rs752687715 | c.1528N>A | p.Glu510Lys | p.E510K | Q92503 | protein_coding | tolerated(0.07) | possibly_damaging(0.738) | TCGA-EA-A3QE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SEC14L1 | SNV | Missense_Mutation | novel | c.2122N>T | p.His708Tyr | p.H708Y | Q92503 | protein_coding | tolerated(1) | benign(0.271) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SEC14L1 | SNV | Missense_Mutation | novel | c.135N>G | p.Phe45Leu | p.F45L | Q92503 | protein_coding | tolerated(0.63) | benign(0.015) | TCGA-UC-A7PD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| SEC14L1 | SNV | Missense_Mutation | rs375335873 | c.2098N>A | p.Ala700Thr | p.A700T | Q92503 | protein_coding | tolerated(0.24) | benign(0.39) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SEC14L1 | SNV | Missense_Mutation | novel | c.539N>A | p.Arg180His | p.R180H | Q92503 | protein_coding | deleterious(0.03) | probably_damaging(0.923) | TCGA-A6-3810-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |